Get started
Author

Francesca Bacchion

Observed name: F. Bacchion
Observed institutions: University of Padua, Eli Lilly (United States), ETH Zurich, Philogen (Italy), Eli Lilly (Italy), Institute of Pharmaceutical Sciences
ORCID: 0009-0005-5108-2338
Observed ORCID: 0009-0005-5108-2338
OpenAlex ID: A5111317569
Organization of the pronephric kidney revealed by large-scale gene expression mapping
2008 · Daniela Raciti, Luca Reggiani, et al. · Genome biology · 110
PDF
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study
2024 · Komal L. Jhaveri, Elgene Lim, et al. · Journal of Clinical Oncology · 49
PDF
Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
2024 · Shripad V. Bhagwat, Cecilia Mur, et al. · Cancer Research · 29
PDF
383MO Imlunestrant with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC): Results from the phase Ia/b EMBER study
2023 · K. Jhaveri, R. Jeselsohn, et al. · Annals of Oncology · 12
PDF
Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study
2024 · Kan Yonemori, Valentina Boni, et al. · Gynecologic Oncology · 11
PDF
SAT0232 A Phase IB Clinical Trial in Rheumatoid Arthritis of Dekavil (F8-IL10), A Novel Anti-Inflammatory Immunocytokine
2014 · M. Galeazzi, L. Bazzichi, et al. · Annals of the Rheumatic Diseases · 3
Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer (aBC): EMBER phase 1a/1b study.
2024 · Manali A. Bhave, Komal L. Jhaveri, et al. · Journal of Clinical Oncology · 2
Abstract PS15-09: Imlunestrant monotherapy and in combination with abemaciclib, with or without an aromatase inhibitor, in estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced breast cancer (aBC): updated results from the EMBER study
2024 · Komal Jhaveri, Elgene Lim, et al. · Cancer Research · 2
Supplemental Table 2 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
2026 · Shripad V. Bhagwat, Cecilia Mur, et al.
Supplemental Table 1 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
2026 · Shripad V. Bhagwat, Cecilia Mur, et al.
Supplemental Table 3 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
2026 · Shripad V. Bhagwat, Cecilia Mur, et al.
Supplemental Table 4 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
2026 · Shripad V. Bhagwat, Cecilia Mur, et al.
Supplemental Figure 1 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
2026 · Shripad V. Bhagwat, Cecilia Mur, et al.
Supplemental Table 5 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
2026 · Shripad V. Bhagwat, Cecilia Mur, et al.
Supplemental Figure 2 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
2026 · Shripad V. Bhagwat, Cecilia Mur, et al.
Supplemental Table 2 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
2025 · Shripad V. Bhagwat, Cecilia Mur, et al.
Data from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
2025 · Shripad V. Bhagwat, Cecilia Mur, et al.
Supplemental Table 5 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
2025 · Shripad V. Bhagwat, Cecilia Mur, et al.
Supplemental Figure 1 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
2025 · Shripad V. Bhagwat, Cecilia Mur, et al.
Supplemental Table 3 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
2025 · Shripad V. Bhagwat, Cecilia Mur, et al.
Supplemental Table 1 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
2025 · Shripad V. Bhagwat, Cecilia Mur, et al.
Supplemental Figure 2 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
2025 · Shripad V. Bhagwat, Cecilia Mur, et al.
Supplemental Table 4 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
2025 · Shripad V. Bhagwat, Cecilia Mur, et al.
Supplemental Table 2 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
2025 · Shripad V. Bhagwat, Cecilia Mur, et al.
Supplemental Figure 1 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
2025 · Shripad V. Bhagwat, Cecilia Mur, et al.
Works count: 31
Citation count: 218
H-index: 5
I10-index: 5
Year
Topic
Type